[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myasthaenia-gravis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myasthaenia-gravis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,75,101,125,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100577511","phase-3-investigating-an-mrna-car-t-cell-therapy-known-as-descartes-08-as-a-potential-approach-to-treat-myasthenia-gravis-100577511",false,"NCT06799247","Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis","A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG)","Inclusion Criteria:\n\n* Patient must be at least 18 years of age.\n* Patient must have generalized myasthenia gravis (gMG), Myasthenia Gravis Foundation of America (MGFA) clinical classification grades 2-4 at the time of Sscreening.\n* MG-Activities of Daily Living (MG ADL) total score ≥ 6.\n* Concomitant immunosuppressive drugs must be deemed necessary by the investigator. The dose must be stable for a minimum of 8 weeks prior to Baseline visit.\n* If a patient is using corticosteroids, the daily dose should not exceed 40 mg\u002Fday of prednisone equivalent. The dose must have been stable for a minimum of 8 weeks prior to Baseline visit.\n* Acetylcholine receptor autoantibody (anti-nAChR) titer or anti-AChR cluster antibody must be above the reference laboratory upper normal limit (UNL) and documented within the past 10 years of screening.\n* Patient must be willing to return for all study visits.\n* Patient must be able to give written informed consent.\n* Women of childbearing potential must agree to use highly effective birth control from Screening until 14 days post last dose of Descartes-08,\n\nExclusion Criteria:\n\n* Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.\n* Diagnosis of gMG within 12 months of screening.\n* No history of systemic treatment for gMG other than acetylcholine esterase inhibitors.\n* Diagnosis of a neuromuscular disease other than gMG.\n* Patient is pregnant or lactating.\n* Treatment with intravenous immunoglobulin (IVIG) or plasma exchange within 4 weeks prior to the Baseline visit.\n* Treatment with rituximab or ocrelizumab within 12 months prior to Baseline visit; treatment with calcineurin inhibitors (e.g. tacrolimus, cyclosporine, cyclophosphamide), Neonatal Fc receptor antagonists, and\u002For other biologics within 3 weeks prior to planned leukapheresis and within 8 weeks prior to Baseline visit.\n* The patient has started treatment with a complement 5a (C5a) inhibitor, such as eculizumab, within 8 weeks of Baseline visit. (NOTE: patients who have been receiving a C5a inhibitor for more than 8 weeks and meet other criteria for enrollment are eligible for treatment).\n* Prior treatment with B-cell maturation antigen (BCMA)-directed therapy (e.g. monoclonal antibody, T-cell engager, or chimeric antigen receptor T-cell \\[CAR-T\\]).\n* Abnormal prothrombin (PT)\u002Finternational normalized ratio (INR) or partial thromboplastin time (PTT) increased \\> 1.5-fold above the normal range at Screening or patient is on anticoagulation therapy (except in cases of elevated PTT with documented lupus anticoagulant; or in patients who have been on stable doses of anticoagulation therapy for more than 6 months of venous thromboembolism (VTE) diagnosis; or in patients on stable doses of anticoagulation therapy for at least 8 weeks of atrial fibrillation diagnosis; these conditions will not be exclusionary unless, in the investigator's opinion, they make participation in the study unsafe).\n* Absolute neutrophil count (ANC) \\\u003C 1000 cells\u002Fmicroliter.\n* Hemoglobin \\\u003C 8.0 g\u002FdL.\n* Platelets \\\u003C 50,000\u002Fmm3.\n* Alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 3x above normal.\n* Creatine clearance less than 30 mL\u002Fmin.\n* History of primary immunodeficiency, organ, or allogeneic bone marrow transplant.\n* Patients must be seronegative for hepatitis B surface antigen.\n* Patients must be seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patients must be tested for the presence of viremia by reverse transcriptase polymerase chain reaction (RT-PCR) and must be hepatitis C virus (HCV) ribonucleic acid (RNA) negative.\n* History of positive human immunodeficiency virus (HIV) or positive HIV at screening.\n* Active tuberculosis or positive QuantiFERON test at screening.\n* Any other clinical or laboratory abnormality that, in the opinion of the investigator, may jeopardize the subject's ability to participate in the study or could affect study outcome.\n* Any active significant cardiac or pulmonary disease that, in the opinion of the Principal Investigator, is significant and\u002For uncontrolled.\n\nNote: Patients with asthma and chronic obstructive pulmonary disease (COPD) controlled with inhaled medications are allowed.\n\n* History of malignancy that required treatment in the past 3 years, except for squamous cell carcinoma, basal cell carcinoma of the skin, or breast or early-stage colon cancer that is surgically removed and did not require adjuvant chemotherapy or radiotherapy.\n* Treatment with any investigational agent 4 weeks prior to screening or 5 half-lives of the investigational drug (whichever is longer).\n* Receipt of a live vaccination within 4 weeks prior to Baseline visit or intent to receive live vaccination during the study (Note: messenger RNA \\[mRNA\\]-based vaccines such as those against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not considered live; likewise, the Janssen Covid-19 vaccine is not live).\n* History of significant recurrent infections or any active infection that in the opinion of the Investigator may interfere with the patient's participation in the opinion of the investigator.\n* Any known psychiatric illness that in the opinion of the Investigator, may interfere with the patient's participation in the study in the opinion of the investigator.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.",[26],"Myasthaenia Gravis",[28,29,30,31,32,33],"myasthenia gravis","CAR-T therapy","Cell Therapy","Decartes-8","BMCA","B cell maturation antigen","RECRUITING","2026-03-23",{"date":37,"type":38},"2026-03-24","ACTUAL",{"date":40,"type":38},"2025-05-06",{"date":42,"type":20},"2027-09-30",{"name":44,"class":45},"Cartesian Therapeutics","INDUSTRY",34,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100623942","a-long-term-follow-up-study-for-participants-previously-treated-with-kyv-101-100623942","NCT07403188","A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101","KYSA-4","Inclusion Criteria:\n\n* Provided informed consent for the LTFU study\n* Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol\n\nExclusion Criteria:\n\n* Not applicable",{"count":55,"type":20},70,"OBSERVATIONAL","The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product).\n\nThis LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).",[59,26,60,61,62,63,64],"Refractory Lupus Nephritis","Stiff Person Syndrome","Rheumatoid Arthritis (RA)","Multiple Sclerosis","Dermatomyositis","Systemic Sclerosis (SSc)","2026-02-03",{"date":67,"type":38},"2026-02-11",{"date":69,"type":38},"2025-11-24",{"date":71,"type":20},"2041-01",{"name":73,"class":45},"Kyverna Therapeutics",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":74},"100574890","phase-3-efgartigimod-in-ivig-dependent-myasthenia-gravis-patients-100574890","NCT06765161","Efgartigimod in IVIG Dependent Myasthenia Gravis Patients","Inclusion Criteria:\n\n* 1\\. Signed informed consent. 2. Age 18-80 years 3. Acetylcholine receptor antibody positive, myasthenia gravis patients, with stable disease for the past four or more months. Stable disease is defined as no change in dosage or interval in IVIG treatments and without any significant change in clinical status.\n\n  4\\. No modification or addition of NSISTs in the past six months 5. No modification or addition in corticosteroid therapy for the past three months 6. Myasthenia Gravis diagnosis was supported by abnormal neurotransmission test or history of improvement with AChE inhibitors.\n\n  7\\. Receiving chronic regular IVIG treatments for myasthenia gravis for the past year or more.\n\nExclusion Criteria:\n\n* 1\\. Patients with previous rituxan or eculizumab treatment or plasma exchange within the past six months 2. Patients with previous thymectomy within the past 3months 3. Patients that have active Hepatitis B, are seropositive for Hepatitis C or HIV or have latent, untreated or active TB or any other significant active infection 4. Patients that have at screening a serum IgG less than 6.0gm\u002FL or a history of chronic hypogammaglobulinemia from any cause.\n\n  5\\. Patients that are pregnant or considering becoming pregnant in the next 6 months.\n\n  6\\. Patients with severe renal impairment (eGFR less than 30ml\u002Fmin) 7. Patients who in the opinion of the investigator should not participate in the study.","80 Years",{"count":83,"type":20},30,[23],"This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.",[26],[88,89,90],"Myasthenia gravis","Vyvgart","IVIG","2025-07-25",{"date":93,"type":38},"2025-07-29",{"date":95,"type":38},"2025-02-06",{"date":97,"type":20},"2027-01-06",{"name":99,"class":100},"Clinique Neuro-Outaouais","OTHER",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":74},"100573006","neuromuscular-complications-of-mek-inhibitors-a-french-case-series-and-a-systematic-review-of-the-literature-100573006","NCT06740656","Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature","Inclusion Criteria:\n\n* Patients with neuromuscular complications of MEK inhibitors used alone or in combination\n* Age \\> 18 years\n\nExclusion Criteria:\n\n* Refusal of data collection",{"count":108,"type":20},5,"MEK inhibitors (trametinib, cobimetinib, selumetinib or binimetinib) have been used since 2016 to treat metastatic melanoma, by targeting the MAPK pathway Neuromuscular complications (neuropathy, myasthenia or myositis) have been reported in patients treated with MEK inhibitors.\n\nWith the growing use of these new oncology therapies, neurologists, oncologists and other clinicians are likely to be increasingly confronted with MEK inhibitor-induced neuropathy, myasthenia or myositis.\n\nYet, so far, these complications have only been documented in a few single case reports.\n\nOur aim was to characterize the neuromuscular complications associated with MEK inhibitors used either alone or in combination.",[111,26,112,113,114],"Myositis","Neuropathy","Guillain Barré Syndrome","Parsonage Turner Syndrome","NOT_YET_RECRUITING","2025-02-16",{"date":118,"type":38},"2025-02-18",{"date":120,"type":20},"2025-03-01",{"date":122,"type":20},"2026-01-01",{"name":124,"class":100},"Central Hospital, Nancy, France",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100568665","phase-2-blinatumomab-in-refractory-myasthenia-gravis-blina-mg-100568665","NCT06684184","Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG)","Safety and Efficacy of Blinatumomab in Refractory Myasthenia Gravis","BLINA-MG","Inclusion Criteria:\n\n* 18 years old ≤ Age ≤ 75 years old\n* patients with a Myasthenia Gravis Activities of Daily Living (MG-ADL) scale score of 6 or higher, and an ocular muscle score constituting less than 50% of the total score\n* after receiving an adequate course of at least two conventional immunotherapeutic drugs (including both steroidal and non-steroidal immunosuppressants), the Post-Intervention Status (PIS) remains unchanged or worsens; or after receiving an adequate course of at least two conventional immunotherapeutic drugs, the PIS improves, but the MG-ADL score is still ≥6 points and persists for at least half a year; or after receiving an adequate course of at least two conventional immunotherapeutic drugs, the PIS is in remission or improvement, yet during the regular tapering of immunotherapeutic drugs, there are still at least two annual exacerbations of disease symptoms (MG-ADL score ≥6 points); or after the occurrence of a crisis, despite multiple immunotherapies such as intravenous immunoglobulin, plasmapheresis, and high-dose intravenous methylprednisolone, and active infection control, the patient still cannot be weaned off the ventilator due to MG-induced respiratory muscle weakness for more than 14 days\n* positive for anti-AChR, and\u002For anti-MuSK, and\u002For anti-LRP4 antibodies.\n* patient or their legal representative signs an informed consent form in writing\n\nExclusion Criteria:\n\n* pregnant or lactating women\n* individuals with an allergy to Blinatumomab\n* individuals who have undergone thymectomy within the 12 months prior to baseline or who are planning to have a thymectomy during the 12-week study period\n* individuals who have received biologic agents targeting CD19 or CD20 within 6 months prior to baseline are eligible for enrollment (subjects with CD19 or CD20 positive B cell counts above the lower limit of normal are allowed to participate)\n* within the 3 months prior to baseline, use of Ecuzumab and Tocilizumab\n* received intravenous immunoglobulin or plasma exchange therapy within 4 weeks prior to baseline\n* currently participating in other clinical studies","75 Years",{"count":135,"type":20},10,[137,23],"PHASE2","The goal of this clinical trial is to evaluating the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis and exploring the immunological mechanisms of Blinatumomab therapy in refractory myasthenia gravis. The main questions it aims to answer are:\n\nWill Blinatumomab improve the symptoms of participants? What medical problems do participants have when using Blinatumomab?\n\nParticipants will:\n\nContinuous intravenous infusion of Blinatumomab for 5 days, pause for one week, and continue continuous intravenous infusion for 5 days Visit the clinic once every 1 month for checkups and tests Keep a diary of their symptoms",[26],"2024-11-10",{"date":142,"type":38},"2024-11-12",{"date":144,"type":20},"2024-11-30",{"date":146,"type":20},"2026-06-30",{"name":148,"class":100},"Zhongming Qiu",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":158,"studyType":56,"phases":4,"briefSummary":159,"conditions":160,"keywords":173,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":74},"100563559","myasthenia-gravis-foundation-of-america-global-mg-patient-registry-100563559","NCT06617741","Myasthenia Gravis Foundation of America Global MG Patient Registry","MGFAPR","Inclusion Criteria:\n\n* age over 18\n* positive MG diagnosis\n\nExclusion Criteria:\n\n* age under 18\n* misdiagnosed with MG",{"count":157,"type":20},3800,"15 Years","The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States. The main questions it aims to answer are:\n\n* How and when are people with MG diagnosed?\n* What are the most common symptoms associated with MG?\n* What treatments are being used to treat MG?\n* What are the impacts of MG on activities of daily living, employment and quality of life?\n* What are the experiences with exacerbation, hospitalization and healthcare access for people with MG? Participants will answer a survey to enroll in the study, and be invited to fill out an update survey twice a year.",[26,161,162,163,164,165,166,167,168,169,170,171,172],"Myasthenia","Myasthenia Gravis Associated with Thymoma","Myasthenia Gravis Crisis","Myasthenia Gravis Exacerbations","Myasthenia Gravis Generalised","Myasthenia Gravis with Exacerbation (Disorder)","Myasthenia Gravis, Adult Form","Myasthenia Gravis, Generalized","Myasthenia Gravis, Ocular","Myasthenia Gravis, Thymectomy","Myasthenia Gravis","Myasthenia Gravis, MuSK",[174,175,176,177,28],"myasthenia","patient registry","MGFA","Myasthenia Gravis Foundation of America","2024-09-26",{"date":180,"type":38},"2024-09-27",{"date":182,"type":38},"2013-10-12",{"date":184,"type":20},"2029-09-19",{"name":177,"class":100}]